According to Greg Brockman on X, citing user IterIntellectus, an Australian technologist reportedly sequenced his rescue dog's tumor DNA for about $3,000, used ChatGPT and AlphaFold to identify mutated proteins and match drug targets, and designed a custom mRNA cancer vaccine that coincided with a halving of the tumor after the first injection (source: Greg Brockman; original account: IterIntellectus). As reported by Greg Brockman, a genomics professor described the effort as gobsmacking and questioned why similar personalized pipelines are not being rolled out to humans, highlighting potential AGI-enabled drug discovery workflows and rapid translational timelines if regulatory pathways are addressed (source: Greg Brockman). According to the X thread, the reported workflow included DNA sequencing, variant prioritization, neoantigen selection, and mRNA construct design, suggesting a low-cost, consumer-accessible stack that could compress discovery cycles and expand precision oncology opportunities for small labs, startups, and veterinary oncology providers (source: IterIntellectus via Greg Brockman).

According to @godofprompt on X, a viral claim cites that $3,000 in DNA sequencing plus a ChatGPT subscription and free AlphaFold enabled a personalized mRNA cancer vaccine design that reportedly shrank a tumor by 50%, with the original story reported by The Australian about a tech executive who used AI tools to create a vaccine for his dog. According to The Australian, the workflow combined next-generation sequencing, protein structure prediction via AlphaFold, and LLM-guided analysis and design, dramatically compressing cost and time compared with traditional academic pipelines. As reported by The Australian, the case underscores emerging business opportunities for AI-driven precision oncology tooling—such as turnkey neoantigen discovery, LLM-assisted peptide ranking, and GMP-ready vaccine design—but it also raises regulatory, clinical validation, and safety concerns requiring oversight and reproducibility. According to The Australian, the practical takeaway for industry is the rising demand for end-to-end platforms that integrate sequencing, neoantigen calling, structure prediction, immunogenicity scoring, and manufacturability checks with audit trails, which could enable clinics and biotech startups to operationalize patient-specific vaccines faster while maintaining compliance.

According to @gdb (Greg Brockman) referencing @sebkrier, a report from The Australian details how tech executive Paul Conyngham used AI tools, including ChatGPT, to help design a custom mRNA vaccine that put his dog’s cancer into remission, marking what the article calls the first personalized cancer vaccine designed for a dog. According to The Australian, Conyngham leveraged AI-assisted literature review, target epitope selection, and sequence design workflows to rapidly prototype a bespoke mRNA construct, then partnered with contract labs for synthesis and veterinary oversight, compressing timelines and costs typically associated with oncology R&D. As reported by The Australian, the case underscores emerging commercial opportunities for AI-guided neoantigen discovery, low-volume GMP manufacturing, and veterinary oncology platforms that offer precision immunotherapy for pets, while raising regulatory and safety considerations for off-label and experimental use. According to The Australian, the workflow combined conversational AI for protocol drafting with bioinformatics-style sequence design, offering a template for startups to productize AI copilots for mRNA vaccine design, quality control checklists, and lab-to-clinic orchestration in the veterinary market.

According to The Rundown AI, an AI consultant without formal biology training used ChatGPT and AlphaFold to design a personalized mRNA cancer vaccine for his rescue dog, leading to a reported 50 percent tumor reduction; UNSW structural biologist Dr. Kate Michie called it encouraging that a non-scientist could execute such a pipeline. As reported by The Rundown AI, the workflow combined large language model-assisted peptide selection with AlphaFold structure predictions to inform neoantigen design, culminating in a custom mRNA formulation. According to The Rundown AI, while this is a single anecdotal outcome and not clinical evidence, it highlights emerging opportunities for AI-enabled neoantigen discovery tools, LLM copilots for wet-lab design, and contract manufacturing platforms offering rapid mRNA vaccine turnaround for veterinary oncology.